Methoxetamine is not approved for medical use and is not formulated or available for clinical use. Therefore, individuals are considered to be taking methoxetamine on their own initiative and not on the advice of a duly licensed physician. This is consistent with data from seizures by law enforcement agencies and case reports suggesting that individuals are taking methoxetamine on their own initiative rather than on the advice of a licensed physician. Synesthesia has been reported in some subjects. The most common form was the visual perception of auditory stimuli. For some, all the sensory impulses seemed to merge: « It was totally weird. The piece looked like a painting by Salvador Dali. None of the laws of physics seemed to be valid anymore and all my senses merged into a mush of surrealism. In humans, methoxetamine users report dissociative anaesthetic and hallucinogenic effects similar to those of PCP and ketamine, including euphoria, increased empathy, dissociation from the body, vivid visual hallucinations, and pleasurable intensification of sensory experiences. Delusions, tachycardia, hypertension, agitation, aggression and cerebellar toxicity have also been reported. Overdoses and deaths associated with methoxetamine have been reported in the scientific literature and by international authorities between 2011 and 2019.
This PDF is the current document as it appeared on 12.06.2021 at 8:45 am during the public inspection. It was viewed 16 times during the public inspection. « I`ve had bad trips before, but no reading in the world could have prepared me for it, » one user wrote. MXE has been one of the few substances covered by the 1971 United Nations Convention on Psychotropic Substances since its inception. It became a Schedule II drug in November 2016. [44] The visual geometry in MXE can be described as very dark and bland compared to ketamine or DXM, and often consists of many small, nested and woven lines. It does not go beyond level 4 and can be exhaustively described by its variations as simplistic in complexity, algorithmic in style, synthetic in sentiment, unstructured in organization, dimly lit in lighting, multicolored in pattern, bright in shading, soft in edges, small in size, slow in speed, Smooth in movement, equal in rounded and angular corners, immersive in depth and constant in intensity. Interested persons may submit written comments on this proposal in accordance with 21 CFR 1308.43(g). The Federal Electronic Records Management System will not accept comments after 11:59 p.m. Eastern Time on the last day of the comment period. To ensure proper handling of comments, please refer to « Docket No. DEA-568 » to all electronic and written correspondence, including all annexes.
Methoxetamine, also known as MXE, 2-(ethylamino)-2-(3-methoxyphenyl)cyclohexan-1-one or 2-(3-methoxyphenyl)-2-(N-ethylamino)cyclohexanone, has a molecular weight of 247.338 g/mol. Methoxetamine is mainly present in the form of white crystalline powder and has also been described as cream, beige or yellow. The Chemical Abstract Service Registry Numbers for methoxetamine are 1239943-76-0 for methoxetamine and 1239908-48-5 for methoxetamine as hydrochloride salt. Its molecular formula (in base form) is C15 H21 NO2. Methoxetamine hydrochloride (salt) is soluble in organic solvents such as ethanol (10 mg/ml) at 25 °C, dimethyl sulfoxide (DMSO) (14 mg/ml) and dimethylformamide (5 mg/ml). It is also soluble in aqueous solvents such as phosphate buffer pH 7.2 (5 mg/ml). The synthesis and characterization of methoxetamine and analytical data (nuclear magnetic resonance spectroscopy, mass spectroscopy and infrared spectroscopy) are reported in the scientific literature. On the drug forum Erowid, users describe MXE as a powerful drug that puts them in a euphoric dream world for hours – a happy place for some, but stressful for others.
2. Disposal of stocks. Any person who is unwilling or unable to obtain Schedule I listing would be required to transfer or transfer all quantities of methoxetamine currently held to a person registered with the DEA prior to the effective date of a final planning action in accordance with all federal, state or state laws. applicable local and tribal authorities.
